SF3B1 and B-cell chronic lymphocytic leukemia: The median treatment-free survival was 66 months vs. 140 months for CLL cases with or without SF3B1 mutations, respectively (hazard ratio [HR] 1.8 (95% CI 0.89–5.24), log-rank test p = 0.094) (Figure 2B).